Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders
09 February 2024 - 12:05AM
Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the
“Company”), a biopharmaceutical company focused on developing novel
therapeutics for serious chronic gastrointestinal (GI) diseases,
today announced the appointments of Bruce Sands, MD, MS and Florian
Rieder, MD to its Clinical Advisory Board (CAB). Drs. Sands and
Rieder will be advising Palisade on the advancement of its product
candidates from preclinical studies to clinical trials.
“We are committed to advancing the treatment
landscape for Inflammatory Bowel Disease (IBD) and believe that the
appointment of these preeminent key opinion leaders will assist in
the development of a precision approach for IBD treatment,”
commented J.D. Finley, Chief Executive Officer of Palisade. “The
leadership and guidance that Drs. Sands and Rieder bring to our CAB
will greatly assist us as we advance the development of our
program, beginning with our lead asset PALI-2108 for the treatment
of ulcerative colitis, which remains on track for the launch of a
Phase 1 clinical study next year.”
About Bruce Sands MD, MS
Bruce Sands, MD, MS is the Dr. Burrill B. Crohn
Professor of Medicine. Dr. Sands is an expert in the management of
IBD and has earned an international reputation for his care of
patients with complex and refractory disease. He joined Mount Sinai
in 2010 as Chief of the Dr. Henry D. Janowitz Division of
Gastroenterology. Prior to joining Mount Sinai, Dr. Sands was
Medical Co-Director of the Crohn's & Colitis Center at
Massachusetts General Hospital in Boston, where he also served as
the hospital's Acting Chief of the Gastrointestinal Unit as well as
Associate Professor of Medicine at Harvard Medical School.
A longtime advocate for the continued
translational research in Crohn's disease and ulcerative colitis,
Dr. Sands is widely recognized for his innovative treatment of IBD
and for his clinical investigations of new therapeutics. He was
among the first to report the efficacy of infliximab-a drug used to
treat autoimmune diseases-in ulcerative colitis, a result later
confirmed in large, multi-center randomized controlled trials. Dr.
Sands was also principal investigator for the landmark ACCENT II
study, an international project that demonstrated the efficacy of
the anti-tumor necrosis factor antibody infliximab as a long-term
treatment for fistulizing Crohn's disease.
Dr. Sands' research also explores IBD
epidemiology and includes the creation of a population-based cohort
of IBD in Rhode Island, a project that is funded by the Centers for
Disease Control and Prevention.
A leader in several major professional
organizations, Dr. Sands has served as the chair of the Clinical
Research Alliance of the Crohn's Foundation of America, Chair of
the Immunology, Microbiology and Inflammatory Bowel Disease Section
of the American Gastroenterological Association (AGA), and chair of
the International Organization for the Study of IBD. He is an AGA
Fellow (AGAF) and a fellow of the American College of
Gastroenterology (FACG). In 2006 he was named Humanitarian of the
Year by the New England Chapter of the Crohn's and Colitis
Foundation of America, the Crohn’s & Colitis Foundations Henry
D. Janowitz Lifetime Achievement Award and Mount Sinai’s Jacobi
Medallion. Dr. Bruce Sands is a paid advisory board member for
Palisades Bio.
Dr. Sands stated, “I am pleased to join Palisade
Bio's Clinical Advisory Board, and I see tremendous potential in
PALI-2108 as a transformative therapy for Ulcerative Colitis. If
successful, PALI-2108 would offer the convenience of oral delivery
with colonic activation and activity, thereby minimizing systemic
exposure and the risk of adverse events while achieving superior
efficacy. The added potential for a precision medicine approach to
identify patients who can benefit most based on their
PDE4B-associated biomarker profile could lead to a truly superior
risk-benefit profile for this agent in ulcerative colitis.”
About Florian Rieder, MD
Dr. Rieder is Vice Chair, Co-Director of the IBD
section, and Director of the Program for Global Translational IBD
at the Department of Gastroenterology, Hepatology and Nutrition at
the Cleveland Clinic, Cleveland. His clinical focus is patients
with IBD with a special emphasis on the field of pathogenesis,
prediction and therapy of intestinal fibrosis. Dr. Rieder has
published more than 150 articles (h-index 52) and book chapters and
has been recognized for his expertise as indicated through
invitations to clinical guideline steering committees of the
European Crohn’s and Colitis Organization (ECCO). He is lead author
of the ECCO guidelines on Ulcerative colitis and lead author of the
first ECCO clinical consensus on ‘Diagnosis and Management of
Intestinal Fibrosis’. He received multiple international
invitations as a speaker, session chair or conference faculty. Dr.
Rieder serves as an abstract reviewer for all major GI conferences,
he is past associate editor (Clinical and Translational
Gastroenterology) and on several editorial boards of medical
journals. He is proud of his significant ties to the ECCO, which he
served as the chair of Y-ECCO, member of the ECCO operational
board, prior Y-ECCO committee member and member of the scientific
committee. He is past chair of REACH-IBD and Co-Chair of the
Professional Education Committee of the Crohn’s and Colitis
Foundation. Dr. Rieder is the leading PI on the international
Stenosis Therapy and Research (STAR) Consortium with the goal to
build a pathway to test anti-fibrotic medications in stricturing
Crohn’s disease.
Dr. Rieder added, "It is with great enthusiasm
that I join Palisade Bio's Clinical Advisory Board. While we are
excited about both programs, the PALI-1908 program is tailored to
address fibro stenotic Crohn's Disease, an area where there are
currently no FDA-approved therapies. PALI-1908 boasts several
advantages, including oral delivery for patient convenience,
localized activation, and activity in the colon, and a true
pleiotropic mechanism with both anti-inflammatory and anti-fibrotic
properties. This combination of attributes positions PALI-1908 as a
highly competitive candidate in the treatment landscape for fibro
stenotic Crohn's Disease, and we look forward to advancing this
program to meet the pressing needs of these patients."
About Palisade Bio
Palisade Bio is a biopharmaceutical company
focused on developing novel therapeutics for serious chronic
gastrointestinal diseases. The Company believes that by using a
targeted approach with its novel therapeutics it will transform the
treatment landscape. For more information, please go
to www.palisadebio.com.
Forward Looking Statements
This communication contains “forward-looking”
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements regarding the Company’s intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the extent of our cash runway; our
ability to successfully develop our licensed technologies;
estimates about the size and growth potential of the markets for
our product candidates, and our ability to serve those markets,
including any potential revenue generated; future regulatory,
judicial, and legislative changes or developments in the United
States (U.S.) and foreign countries and the impact of these
changes; our ability to maintain the Nasdaq listing of our
securities; our ability to build a commercial infrastructure in the
U.S. and other markets; our ability to compete effectively in a
competitive industry; our ability to identify and qualify
manufacturers to provide API and manufacture drug product; our
ability to enter into commercial supply agreements; the success of
competing technologies that are or may become available; our
ability to attract and retain key scientific or management
personnel; the accuracy of our estimates regarding expenses, future
revenues, capital requirements and needs for additional financing;
our ability to obtain funding for our operations; our ability to
attract collaborators and strategic partnerships; and the impact of
the COVID-19 pandemic or any global event on our business, and
operations, and supply. Any statements contained in this
communication that are not statements of historical fact may be
deemed to be forward-looking statements. These forward-looking
statements are based upon the Company’s current expectations.
Forward-looking statements involve risks and uncertainties. The
Company’s actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation, the Company’s ability to advance its
nonclinical and clinical programs, the uncertain and time-consuming
regulatory approval process; and the Company’s ability to secure
additional financing to fund future operations and development of
its product candidates. Additional risks and uncertainties can be
found in the Company’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2022, filed with the Securities and
Exchange Commission (“SEC”) on March 22, 2023, as well as the
Company’s Quarterly Report on Form 10-Q, for the three and nine
month periods ended September 30, 2023, filed with the SEC on
November 9, 2023. These forward-looking statements speak only as of
the date hereof and the Company expressly disclaims any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in the Company’s expectations with regard thereto or any change in
events, conditions or circumstances on which any such statements
are based.
Investor Relations Contact
JTC Team, LLCJenene Thomas
833-475-8247PALI@jtcir.com
Source: Palisade Bio
- Palisade Bio, Inc.
- Palisade Bio, Inc.
Palisade Bio (NASDAQ:PALI)
Historical Stock Chart
From Apr 2024 to May 2024
Palisade Bio (NASDAQ:PALI)
Historical Stock Chart
From May 2023 to May 2024